Sovaldi (sofosbuvir) waa daawada nucleotide polymerase inhibitor ah ee lagu isticmaalo daweynta antiviral ee isku dhafan ee daaweynta cagaarshow C (HCV) . Sovaldi wuxuu shaqeeyaa isagoo xannibaya enzim ah in HCV ay u isticmaasho si ay ugu soo celiso RNA-ga, si wax ku ool ah u hakiso marxaladda fayraska 'lifecycle'.
Sovaldi waxaa la ansixiyey bishii Diseembar 2013 by Maamulka Maraykanka ee Cuntada iyo Maandooriyaha (FDA) si loogu isticmaalo dadka waaweyn 18 sano ama ka weyn ee HCV genotypes 1, 2, 3 iyo 4 infakshanka, oo ay ku jiraan kuwa qaba hepatocellular carcinoma (nooca ugu badan ee kansarka beerka) iyo shakhsiyaadka qaba HIV / HCV la wadaagista cudurka.
Sovaldi ayaa loo ogolaaday isticmaalka bukaanka hore loo daaweyn (daaweyn-naeef), iyo sidoo kale kuwa qaba qayb ka mid ah ama aan wax laga qabanin daaweynta HCV kahor.
Cilmi-baaris cilmi-baariseed ayaa muujisay in heerka daaweynta-daaweynta bukaanka ku jira nidaamka Sovaldi-ku-saleysan yahay inta u dhexeysa 82% iyo 96%.
Qiyaasta
Midkiiba 400 mg kiniin ah maalin walba la qaato ama aan lahayn cunto. Kiniinada Sovaldi waa jaalaal iyo filim qabooban, oo leh "GSI" oo ka kooban hal dhinac iyo "7977" dhinaca kale.
Soo-jeedinta Talooyinka
Sovaldi waxaa loo qoraa isticmaalka daaweynta isku dhafan ee ribavirin ; oo leh labadaba interferon pegylated (peg-interferon) + ribavirin; ama Daklinza (daclatasvir) . Sovaldi waa inaan waligaa loo isticmaalin sidii monotherapy ah.
Daawooyinka soo socda ayaa lagula talinayaa:
- Genotype 1 ama 4: Sovaldi + peg-interferon + ribavirin 12 toddobaad
- Genotype 2: Sovaldi + ribavirin 12 wiig.
- Genotype 3: Sovaldi + ribavirin mudo 24 isbuuc AMA Sovaldi + Daklinza (daclatasvir) 12 asbuuc
Bukaannada leh genotype 1 kuwaas oo aan xaq u lahayn interferon ama interferon-ku-dulqaadasho, waxaa lagu talinayaa in isku-dar ah Sovaldi + ribavirin la qoro 24 toddobaad.
Wixii bukaan ah oo sugaya in beerka laga bedelo, waa in daaweynaha kor ku xusan lagu qoraa 48 toddobaad ama ilaa inta la sameynayo xubinta beerka, hadba kan soo horeeya.
Saameynada Caadiga ah
Waxyeellooyinka ugu badan ee la xidhiidha isticmaalka Sovaldi + ribavirin (sida, 20% ama ka yar bukaanka) waa:
- Daal
- Madax xanuun
- Lalabbo
Saameynaha ugu badan ee lagu arko bukaanka isticmaalaya Sovaldi + ribavirin + peg-interferon waa:
- Daal
- Madax xanuun
- Lalabbo
- Insomnia
- Anemia
Marka laga reebo dhiig-yarida iyo neutropenia, inta badan saameynta daaweyneed ee la xidhiidha isticmaalka Sovaldi ayaa loo tixgeliyaa mid khafiif ah ama waqti gaaban (Fasalka 1).
Cilmi-baarista kiliinikada 1% ama ka yar ee bukaanka ku jira daaweynta Sovaldi + ribavirin oo aan horey loo ogaan karin sababtoo ah dhibaatooyinka aan la daweyn karin. Xaaladuna waxay kordhay 11% bukaanada ku jira Sovaldi + ribavirin + peg-interferon.
Isdhexgalka daroogada
Kuwa soo socda waa in laga fogaadaa marka la isticmaalayo Sovaldi:
- Dawooyinka anti-tuberculosis ku salaysan Rifampin: Mycobutin, Rifater, Rifamate, Rimactane, Rifadin, Priftin
- Anticonvulsants: Tegretol, Dilantin, Trileptal, phenobarbital
- St. John Wort
Bukaanka qaba HIV , Sovaldi ma ahan in lala wadaago labada Aptivus (tipranavir) ama Norvir (ritonavir) maaddaama kuwan ka mid ah fasalada protease inhibitor lagu daaweyn karo ay hoos u dhigi karaan diirada xajmiga ee Sovaldi.
Khilaafaadka
Sovaldi wuxuu ka hortagaa isticmaalka inta lagu jiro uurka ama ragga ay wadaagaan uurku maadaama ay daraasaadka xayawaanku soo jeediyeen halis suurtagal ah oo ku iman karta cilladaha dhalashada ama dhimashada uurjiifka.
Waxaa lagu talinayaa in dhammaan haweenka ku jira da'da ilmo-dhalista la kormeero bil kasta uurka inta lagu jiro muddada daaweynta. Waxaa sidoo kale lagula talinayaa in bukaanka iyo ragga ragga ah la siiyo ugu yaraan laba hab-hormoon oo aan ahayn hormoonin iyo in loo isticmaalo muddada daaweynta iyo lix bilood kadib.
Xigasho:
Manns, M. iyo Cornberg, M. "Sofosbuvir: caarada ugu dambeysa ee dambaska cagaarshow C?" Lancet. Maarso 15, 2013; 13 (5): 378-379.